LEADER 03972nam 22006015 450 001 9910438005503321 005 20200706172947.0 010 $a1-4471-4297-7 024 7 $a10.1007/978-1-4471-4297-3 035 $a(CKB)2670000000277835 035 $a(EBL)1030449 035 $a(OCoLC)820845395 035 $a(SSID)ssj0000800182 035 $a(PQKBManifestationID)11431316 035 $a(PQKBTitleCode)TC0000800182 035 $a(PQKBWorkID)10765283 035 $a(PQKB)11185124 035 $a(DE-He213)978-1-4471-4297-3 035 $a(MiAaPQ)EBC1030449 035 $a(PPN)168293153 035 $a(EXLCZ)992670000000277835 100 $a20121026d2013 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAntiplatelet and Anticoagulation Therapy /$fedited by Albert Ferro, David A. Garcia 205 $a1st ed. 2013. 210 1$aLondon :$cSpringer London :$cImprint: Springer,$d2013. 215 $a1 online resource (254 p.) 225 1 $aCurrent Cardiovascular Therapy 300 $aDescription based upon print version of record. 311 $a1-4471-4296-9 320 $aIncludes bibliographical references and index. 327 $aAntiplatelet agents: current and novel -- Antiplatelet Drug Resistance and Variability in Response: The Role of Antiplatelet Therapy Monitoring -- Anticoagulant Drugs: Current and Novel -- Primary prevention of cardiovascular disease -- Approaches to the Prophylaxis and Treatment of Venous and Cardiac Thromboembolic Disease. 330 $aAspirin has been in clinical use for over 100 years, making it one of the oldest commonly used drugs in medicine, and is now predominantly used as an antiplatelet agent. Major new antiplatelet drug classes have recently become available for the clinician that offer the promise of major improvements in the treatment and prevention of arterial thrombotic disease. In the field of anticoagulation, the vitamin K antagonists such as warfarin have not been available for as long as aspirin in the antiplatelet field, and have also had very little in the way of competition until recently; although a number of parenteral anticoagulants have been available, the vitamin K antagonists have been the only orally active anticoagulant drugs. The last few years have seen the arrival of new drug classes, the orally active direct thrombin inhibitors and factor Xa antagonists, which offer a number of advantages, but not without important drawbacks. In the face of these important advances in both antiplatelet and anticoagulant therapy, clinicians often feel confused, even overwhelmed, as to what is now available and which drugs are useful (and indicated) in which circumstances. Antiplatelet and Anticoagulant Therapy is designed with such people in mind. It is written in an easy-to-follow format and with many illustrations to aid clarity and the assimilation of information. Each chapter is written by established authorities in their fields who are also experienced in explaining often complex concepts. The result is a unique book which is not only comprehensive but also clear and useful for the busy medical practitioner. 410 0$aCurrent Cardiovascular Therapy 606 $aCardiology 606 $aMedicine 606 $aCardiology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33037 606 $aMedicine/Public Health, general$3https://scigraph.springernature.com/ontologies/product-market-codes/H00007 615 0$aCardiology. 615 0$aMedicine. 615 14$aCardiology. 615 24$aMedicine/Public Health, general. 676 $a617.413 702 $aFerro$b Albert$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aGarcia$b David A$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910438005503321 996 $aAntiplatelet and Anticoagulation Therapy$92079575 997 $aUNINA